Isomorphic Labs, an AI drug discovery startup founded by Demis Hassabis, has secured $2.1 billion in Series B funding led by Thrive Capital. The company plans to use the new capital to scale its compute resources, generate more data, and expand its drug development programs. Isomorphic aims to build a platform capable of solving all diseases, rather than focusing on individual drug successes, leveraging AI to understand the informational structure of biology. AI
IMPACT Accelerates AI's application in drug discovery, potentially speeding up the development of new treatments for diseases.
RANK_REASON Significant funding round for an AI-focused company. [lever_c_demoted from significant: ic=1 ai=0.7]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
